Mounjaro and Gallbladder Disease: When to Call the Doctor

What does the Mounjaro label say about gallbladder disease?

Mounjaro carries a Warning and Precaution for acute gallbladder disease. In the label's placebo-controlled trials in adults, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. The warning's statement is specific: if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated [1].

Mounjaro is approved for type 2 diabetes in adults and children 10 years and older, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk; it is not labeled for weight loss [1].

What does the label say about pancreatitis?

For pancreatitis, a separate Mounjaro warning, the label describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, the label says to discontinue Mounjaro and begin appropriate management [1].

How common is gallbladder disease with tirzepatide?

A 2023 meta-analysis of nine randomized trials with 9,871 participants found that tirzepatide was associated with a higher composite of gallbladder or biliary disease versus placebo or basal insulin (RR 1.97; 95% CI 1.14 to 3.42), but not with a significant increase in cholelithiasis, cholecystitis or biliary disease when each was analyzed separately [3]. A 2025 meta-analysis of 21 GLP-1 receptor agonist trials including 99,599 patients found a 26% increase in gallbladder disorders across the class, which included tirzepatide [2].

The picture is not uniform. A 2025 meta-analysis of 13 trials in 26,894 people with obesity but without diabetes found that semaglutide increased gallbladder-related disorders, particularly cholelithiasis, while tirzepatide showed no significant biliary risk in that pooled analysis [5].

What might contribute to gallbladder risk?

Tirzepatide is a dual GIP and GLP-1 receptor agonist that delays gastric emptying [1]. A review of GLP-1-based therapies says their effects on the gallbladder may be beneficial but also potentially increase the risk of biliary disease [6].

Rapid weight loss is a gallstone risk factor. A 1995 meta-analysis of prospective studies in people losing weight found a dramatically increasing risk of gallstone formation at rates of weight loss above 1.5 kg per week, and its authors suggested rates should not exceed an average of 1.5 kg per week [4]. In SURPASS-2, a 40-week trial in adults with type 2 diabetes on metformin, weight loss was greater with tirzepatide than with semaglutide 1 mg [7]. These findings do not establish why an individual Mounjaro user develops gallbladder disease.

Common Mounjaro side effects in the label

In the label's pooled adult trials, the most common adverse reactions with Mounjaro were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain. Nausea occurred in 4% on placebo, 12% on 5 mg, 15% on 10 mg and 18% on 15 mg; vomiting in 2%, 5%, 5% and 9%; abdominal pain in 4%, 6%, 5% and 5% [1]. The label lists biliary colic separately, within acute gallbladder disease [1].

What lowers gallstone risk during weight loss?

A 2014 meta-analysis of 13 randomized trials in 1,836 participants found that ursodeoxycholic acid reduced ultrasound-verified gallstones during weight loss (RR 0.33; 95% CI 0.18 to 0.60; number needed to treat 9). Higher-fat weight-loss diets also reduced gallstones compared with low-fat diets (RR 0.09; 95% CI 0.01 to 0.61) [8].

Those trials were in people losing weight through diet or bariatric surgery, not in people taking tirzepatide. We found no study that tested ursodiol specifically in Mounjaro-treated patients.